---
title: "Pembrolizumab"
slug: "pembrolizumab"
date: "2023-10-09"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ªï¼š[[Preoperative Chemotherapy for Operable Breast Cancer]]

# Pembrolizumab

( Keytruda )

- Mechanism: Binds to PD-1
- Dosing: 2 mg/kg IV every 3 wks, tx can be held due to â†‘ liver enzymes
- PK/PD: T1/2 âˆ¼27 d
- AEs: Immune-mediated tox, fatigue, rash, metabolic abnormalities, lymphocytopenia
- DDI: No known pathways of metabolism
- Clinical pearls: Tx immune-related tox w/ steroids (prednisone 1-2 mg/kg/d)

### Backlink

- [[systemic therapy of breast cancer]]
- [[prechemo_TNBC]]
- [[irAE]]
- [[Stage II-of-Preoperative Chemotherapy for Operable Breast Cancer]]
- [[Stage III-of-Preoperative Chemotherapy for Operable Breast Cancer]]
- [[Pembrolizumab plus Chemotherapy in Metastatic Nonâ€“Small-Cell Lung Cancer]]
- [[PD-L1]]
- [[Overview-immunotherapy and cellular therapy]]
- [[NSCLC Treatment]]
- [[Metastatic Colon Cancer]]
- [[KEYNOTE-177]]
- [[KEYNOTE-181]]
- [[Immunotherapy]]
- [[Amivantamab]]
- [[Adeno or Other in Stage IV NSCLC Treatment]]
